Successful Treatment of Interstitial Lung Disease in STAT3 Gain-of-Function Using JAK Inhibitors

Am J Respir Crit Care Med. 2020 Sep 15;202(6):893-897. doi: 10.1164/rccm.201906-1204LE.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Child
  • Child, Preschool
  • Female
  • France
  • Gain of Function Mutation
  • Humans
  • Infant
  • Janus Kinase Inhibitors / therapeutic use*
  • Lung Diseases, Interstitial / drug therapy*
  • Lung Diseases, Interstitial / genetics*
  • Male
  • Pyrazoles / therapeutic use*
  • STAT3 Transcription Factor / drug effects*
  • STAT3 Transcription Factor / genetics*
  • Texas

Substances

  • Antibodies, Monoclonal, Humanized
  • Janus Kinase Inhibitors
  • Pyrazoles
  • STAT3 Transcription Factor